الفهرس 
CHRONIC LYMPHOCYTIC LEUKEMIAOnly 14 pages are availabe for public view
 |  | from | 51 |  |  |
| | | from | 51 | | |
Abstract
Chronic lymphocytic leukemia is one of the most common lymphoid
malignancies, accounting for approximately 11% of all hematologic
neoplasms.
CLL patients have an extremely variable clinical course, ranging from
stable conditions not requiring therapy to rapidly advancing disease
demanding immediate treatment. Thus, prognostic factors are needed to
identify patients who will require immediate therapy.
CD38 is a transmembrane glycoprotein that is regulated by the tumor
microenvironment and can function as a receptor and as an enzyme.
The aim of this study was to evaluate CD38 expression on the Blymphocytes
of patients with chronic Lymphocytic Leukemia compared
with healthy controls to use it as a prognostic marker.
This study included 40 patients (34 males and 6 females) their ages
ranged from 33 to 80 years and 25 apparently healthy individuals were
included as a control group (19 males and 6 females) their ages ranged
from 30 to 78 years.
The results showed the following:
• There was highly significant elevation in CLL cases than controls
regarding TLC and lymphocyte%, this can be explained by increased
production and prolonged lifespan of lymphocytes with impaired
apoptosis.
There was highly signif.